New drug combo aims to outsmart resistant lung cancer
NCT ID NCT06106802
First seen Mar 03, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study tests a combination of two targeted drugs, lazertinib and tepotinib, in people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) that has stopped responding to lazertinib alone due to a change in the MET gene. About 47 participants will receive the drug combination to see if it can shrink tumors or slow cancer growth. The goal is to find a new treatment option for when the first therapy stops working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-gu, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.